Brinter
Finnish bioprinting hardware company developing modular multi-material 3D bioprinting systems for tissue engineering, biomedical research, and regenerative medicine implants.
- CEO / Founder
- Tomi Kalpio
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $3.52M
- Latest Round
- Seed
- Key Investors
- Innovestor; Athensmed; Plug and Play Tech Center; Techstars; Winston Starts; Business Finland; European Union; European Space Agency (ESA)
Technology & Products
Key Products
Modular multi-material 3D bioprinters (Brinter One/Brinter Core), 3D bioprinted regenerative tissue implants for orthopedic and aesthetic applications
Technological Advantage
Modular platform enabling multiple bioprinting modalities in one system
Differentiation
Value Proposition
Modular multi-material 3D bioprinting platform for scalable advanced tissue manufacturing and regenerative implants
How They Differentiate
Modular multi-material approach with scalable bioprinting platform for regenerative tissue implant manufacturing
Market & Competition
Target Customers
Research institutions, pharmaceutical companies, hospitals
Industry Verticals
Biotechnology, Pharmaceuticals, Research, Healthcare, Manufacturing
Competitors
Desktop Health, Aspect Biosystems, Allevi
Growth & Milestones
Growth Metrics
Active in 10+ countries including Germany and UK; revenue estimated $1–10M range (LeadIQ)
Major Milestones
Founded (3DTech/Brinter origin); 2020: Launched Brinter brand; 2021: €1.2M seed funding (Innovestor, Athensmed); 2023: Pre-Seed $750K; Selected by Redwire Space NV as bioprinter supplier for ESA ISS 3D-BioSystem Facility (Advanced Tissue Manufacturing project); Collaboration established with UPM Biomedicals
Notable Customers
Research institutions; Pharmaceutical companies; Redwire Space NV / European Space Agency (bioprinter supplier for ISS Advanced Tissue Manufacturing project)